Alzheimer’s disease (AD) begins to alter and damage the brain years — even decades — before symptoms appear, making early identification of AD risk paramount to slowing its progression.
In a new study published online in the September 9, 2019 issue of the Neurobiology of Aging, scientists at University of California San Diego School of Medicine say that, with further developments, measuring how quickly a person’s pupil dilates while they are taking cognitive tests may be a low-cost, low-invasive method to aid in screening individuals at increased genetic risk for AD before cognitive decline begins.
In recent years, researchers investigating the pathology of AD have primarily directed their attention at two causative or contributory factors: the accumulation of protein plaques in the brain called amyloid-beta and tangles of a protein called tau. Both have been linked to damaging and killing neurons, resulting in progressive cognitive dysfunction.
The new study focuses on pupillary responses which are driven by the locus coeruleus (LC), a cluster of neurons in the brainstem involved in regulating arousal and also modulating cognitive function. Tau is the earliest occurring known biomarker for AD; it first appears in the LC; and it is more strongly associated with cognition than amyloid-beta. The study was led by first author William S. Kremen, PhD, and senior author Carol E. Franz, PhD, both professors of psychiatry and co-directors of the Center for Behavior Genetics of Aging at UC San Diego School of Medicine.
The LC drives pupillary response — the changing diameter of the eyes’ pupils — during cognitive tasks. (Pupils get bigger the more difficult the brain task.) In previously published work, the researchers had reported that adults with mild cognitive impairment, often a precursor to AD, displayed greater pupil dilation and cognitive effort than cognitively normal individuals, even if both groups produced equivalent results. Critically, in the latest paper, the scientists link pupillary dilation responses with identified AD risk genes.
“Given the evidence linking pupillary responses, LC and tau and the association between pupillary response and AD polygenic risk scores (an aggregate accounting of factors to determine an individual’s inherited AD risk), these results are proof-of-concept that measuring pupillary response during cognitive tasks could be another screening tool to detect Alzheimer’s before symptom appear,” said Kremen.
The Latest on: Diagnosing Alzheimer’s
via Google News
The Latest on: Diagnosing Alzheimer’s
- Alzheimer's Disease Diagnostics and Therapeutics Market - Global Growth, Trends, and Forecasts Report 2020-2025 - ResearchAndMarkets.comon January 15, 2021 at 7:32 am
The "Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The global Alzheimer's disease ...
- New Alzheimer's research could inspire better treatments and earlier diagnosison January 15, 2021 at 4:22 am
Neuroscientists at the University of Portsmouth, with collaborators in the UK and the U.S., have made a breakthrough in the study of Alzheimer's which could inspire better treatments and earlier ...
- AltPep Raises $23M Jumpstarting Work on Alzheimer's Diseaseon January 14, 2021 at 7:02 pm
AltPep Corporation, a privately held biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer's Disease, today announced it closed a $23.
- Primary Progressive Aphasia in Alzheimer's Doesn't Foretell Memory Losson January 13, 2021 at 1:03 pm
Memory was preserved over time in people who had primary progressive aphasia (PPA) with Alzheimer's disease, a small study showed. Episodic memory was preserved at initial testing and did not decline ...
- Brain mapping device uses LEDs to fight Alzheimerson January 13, 2021 at 6:38 am
News; Brain mapping device uses LEDs to fight Alzheimers. ; IMediSync has unveiled its iSyncWave, a brain mapping and personalised NIR-LED therapy designed to enhance n ...
- Blood Test May Help Diagnose Alzheimer's Disease, Scientists Sayon January 12, 2021 at 8:20 pm
A simple blood test may soon be available so that doctors can diagnose patients with two common forms of dementia – Alzheimer's disease and frontotemporal dementia (FTD) ...
- Alzheimer's Progression Tracks With Blood Biomarkerson January 12, 2021 at 3:11 pm
Blood-based biomarkers paralleled the progression of Alzheimer's disease neurodegeneration, a large longitudinal cohort study showed. Increases of phosphorylated tau at threonine 181 (p-tau181) in ...
- This Is the State Where Alzheimer's Causes the Most Deathson January 12, 2021 at 11:55 am
The annual Alzheimer’s death rate has more than doubled, from 17.6 deaths per 100,000 residents in 2000 to 37.3 deaths per 100,000 residents in 2018, according to data from the National Center for ...
- New drug and blood test developed for Alzheimer'son January 12, 2021 at 11:25 am
The new drug may slow the rate of cognitive decline, and the new blood test is easier to administer. Neither have FDA approval yet.
- An Aggressive New Alzheimer’s Drug Is Raising Hope With Promising Trialson January 11, 2021 at 2:05 pm
A small trial of an experimental Alzheimer’s drug developed by Eli Lilly has shown promise in treating the degenerative disease, which has proven very difficult to treat over the years. The drug, ...
via Bing News